RT Journal Article
SR Electronic
T1 Benefits of Surveillance Testing and Quarantine in a SARS-CoV-2 Vaccinated Population of Students on a University Campus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.15.21258928
DO 10.1101/2021.06.15.21258928
A1 Francis C. Motta
A1 Kevin A. McGoff
A1 Anastasia Deckard
A1 Cameron R. Wolfe
A1 M. Anthony Moody
A1 Kyle Cavanaugh
A1 Thomas N. Denny
A1 John Harer
A1 Steven B. Haase
YR 2021
UL http://medrxiv.org/content/early/2021/06/18/2021.06.15.21258928.abstract
AB Surveillance testing and quarantine have been effective measures for limiting SARS-CoV-2 transmission on university campuses. However, the importance of these measures needs to be re-evaluated in the context of a complex and rapidly changing environment that includes vaccines, variants, and waning immunity. Also, recent guidelines from the CDC suggest that vaccinated students do not need to participate in surveillance testing. We used an agent-based SEIR model to evaluate the utility of surveillance testing and quarantine in a fully vaccinated student population where vaccine effectiveness may be impacted by the type of vaccination, the presence of variants, and the loss of vaccine-induced or natural immunity over time. We found that weekly surveillance testing at 90% vaccine effectiveness only marginally reduces viral transmission as compared to no testing. However, at 50%-75% effectiveness, surveillance testing can provide over 10-fold reduction in the number of infections on campus over the course of the semester. We also show that a 10-day quarantine protocol for exposures has limited effect on infections until vaccine effectiveness drops to 50%, and that increased surveillance testing for exposures is at least as effective as quarantine at limiting infections. Together these findings provide a foundation for universities to design appropriate mitigation protocols for the 2021-2022 academic year.Competing Interest StatementDr. Wolfe reported receiving drug development consulting fees not related to this study from Enzychem Lifesciences, and participated on data safety and monitoring boards or advisory boards including for Merck concerning antivirals for CMV, for Biogen and Atea Pharmaceuticals concerning antivirals for COVID-19, and for Janssen concerning vaccines for respiratory viruses within the 36 months preceding this study. Dr. McGoff reported receiving funding from the NSF during the conduct of the study. No other disclosures were reported.Funding StatementDr. McGoff was partially supported by the National Science Foundation under award DMS-1847144. No other external funding was used to support the research contained in this study and no authors received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data, model, and scripts used to perform the analyses and generate the figures and tables presented in this study are available at https://gitlab.com/duke-covid-modeling/covid_campus_interventions_public https://gitlab.com/duke-covid-modeling/covid_campus_interventions_public